Mereo BioPharma Group PLC ADR Cash Flow Conversion Efficiency
Mereo BioPharma Group PLC ADR cash flow conversion efficiency. Based on the latest financial reports, Mereo BioPharma Group PLC ADR (MREO) has a cash flow conversion efficiency ratio of -0.211x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.04 Million) by net assets ($28.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mereo BioPharma Group PLC ADR (2015–2025)
Cash flow conversion efficiency of Mereo BioPharma Group PLC ADR from 2015 to 2025. This chart illustrates how Mereo BioPharma Group PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Mereo BioPharma Group PLC ADR stock price for real-time trading data and today's change.
Mereo BioPharma Group PLC ADR Cash Flow Conversion Ratio Explained
Mereo BioPharma Group PLC ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mereo BioPharma Group PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mereo BioPharma Group PLC ADR ranked by their cash flow conversion efficiency. Also see how much is Mereo BioPharma Group PLC ADR worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Analabs Resources Bhd
KLSE:7083
|
-0.013x |
|
Daehan New Pharm Co. Ltd
KQ:054670
|
0.034x |
|
Il Sung Const
KO:013360
|
-0.390x |
|
LightInTheBox Holding Co Ltd ARD
NYSE:LITB
|
-2.224x |
|
SIL Investments Limited
NSE:SILINV
|
0.027x |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
N/A |
|
Promateris SA
RO:PPL
|
N/A |
|
Sietel Ltd
AU:SSL
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Mereo BioPharma Group PLC ADR (2015–2025)
The table below shows the annual cash flow conversion efficiency of Mereo BioPharma Group PLC ADR from 2015 to 2025. Review MREO FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $40.92 Million | $-30.97 Million | -0.757x | -40.56% |
| 2024-12-31 | $60.97 Million | $-32.83 Million | -0.539x | -28.79% |
| 2023-12-31 | $50.54 Million | $-21.13 Million | -0.418x | +55.97% |
| 2022-12-31 | $51.40 Million | $-48.82 Million | -0.950x | -1498.58% |
| 2021-12-31 | $119.01 Million | $-7.07 Million | -0.059x | -103.15% |
| 2020-12-31 | $-20.47 Million | $-38.62 Million | 1.887x | +267.05% |
| 2019-12-31 | $53.33 Million | $-60.22 Million | -1.129x | -59.95% |
| 2018-12-31 | $32.77 Million | $-23.14 Million | -0.706x | -37.23% |
| 2017-12-31 | $62.48 Million | $-32.15 Million | -0.515x | -48.83% |
| 2016-12-31 | $79.26 Million | $-27.40 Million | -0.346x | -424.01% |
| 2015-12-31 | $101.54 Million | $-6.70 Million | -0.066x | -- |
About Mereo BioPharma Group PLC ADR
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navi… Read more